Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab Phase 2 in Hidradenitis Suppurativa
NCT03248531Phase 2Completed
- Sponsor
- UCB
- Start
- Sep 2017
- Primary completion
- Nov 2018
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of bimekizumab in hidradenitis suppurativa (HS) (3 arms), sponsored by UCB. Primary endpoint: Hidradenitis Suppurativa Clinical Response at 12 weeks. Started Sep 2017; status: completed.
02
Drugs
bimekizumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT03248531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03248531.